Details of Disease

Disease Name

Invasive breast carcinoma

BRCA; invasive mammary carcinoma; invasive breast carcinoma; infiltrating carcinoma of breast; infiltrating breast carcinoma; infiltrating carcinoma of the breast; invasive breast cancer; invasive carcinoma of breast; invasive carcinoma of the breast; infiltrating breast cancer

Definition

A carcinoma that infiltrates the breast parenchyma. The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU). Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ. It is the most common carcinoma affecting women.

Disease Hierarchy

:

DIS2UE88: Breast carcinoma

DISANYTW: Invasive breast carcinoma

Disease Identifiers

MONDO ID

MONDO_0006256

UMLS CUI

C0853879

MedGen ID

163435

SNOMED CT ID

713609000

General Information of Disease (ID: DISANYTW)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 51 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BCL6	TTC9YX5	Limited	Altered Expression	[1]
BRCA2	TTUARD6	Limited	Genetic Variation	[2]
CD1A	TTBGTFN	Limited	Altered Expression	[3]
CYP2D6	TTVG215	Limited	Genetic Variation	[4]
EPCAM	TTZ8WH4	Limited	Biomarker	[5]
EPHB6	TTZEMUY	Limited	Altered Expression	[6]
FDXR	TT3W4IX	Limited	Altered Expression	[7]
GGH	TTZJRL0	Limited	Biomarker	[8]
IL13RA2	TTMPZ7V	Limited	Altered Expression	[9]
PPM1D	TTENJAB	Limited	Altered Expression	[10]
PYGM	TTZHY6R	Limited	Genetic Variation	[11]
REL	TT1ZCTH	Limited	Biomarker	[12]
TMPRSS2	TT1GM2Z	Limited	Altered Expression	[13]
CCNA2	TTAMQ62	Disputed	Biomarker	[14]
CDH5	TTXLCFO	Disputed	Posttranslational Modification	[15]
FGFBP1	TTV1YFT	Disputed	Biomarker	[16]
GNRH1	TT0ID4A	Disputed	Biomarker	[17]
MAP3K11	TTETX6Q	Disputed	Biomarker	[18]
PBRM1	TTH8ZRL	Disputed	Altered Expression	[19]
PLD2	TTRLMKF	Disputed	Altered Expression	[20]
CA9	TT2LVK8	moderate	Altered Expression	[21]
FKBP1A	TTMW94E	moderate	Altered Expression	[22]
FST	TTDNM9W	moderate	Altered Expression	[23]
KRT19	TT3JF9E	moderate	Altered Expression	[24]
LNPEP	TTY2KP7	moderate	Biomarker	[25]
MAGEA3	TTWSKHD	moderate	Biomarker	[26]
MAP3K21	TTSW9YL	moderate	Altered Expression	[27]
RXRG	TTH029C	moderate	Biomarker	[28]
SNCG	TT5TQNZ	moderate	Altered Expression	[29]
CCN1	TTPK79J	Strong	Biomarker	[30]
CTSA	TT5NILS	Strong	Altered Expression	[31]
CYP19A1	TTSZLWK	Strong	Biomarker	[32]
F2RL2	TTVSEBF	Strong	Biomarker	[33]
FSHR	TTZFDBT	Strong	Altered Expression	[34]
GMNN	TT390KA	Strong	Altered Expression	[35]
IL13RA1	TTNEAMG	Strong	Altered Expression	[36]
OLFM4	TTK1CX7	Strong	Altered Expression	[37]
PTPN14	TTNIR6C	Strong	Altered Expression	[38]
RPS6KA5	TTYXEPL	Strong	Altered Expression	[39]
SEPTIN6	TTAGE7U	Strong	Biomarker	[40]
TOP2A	TTCGY2K	Strong	Altered Expression	[41]
TRIM27	TTTO3QN	Strong	Genetic Variation	[42]
BST2	TT90BJT	Definitive	Altered Expression	[43]
FANCF	TTNZKFJ	Definitive	Posttranslational Modification	[44]
FOXQ1	TTEJZOL	Definitive	Altered Expression	[45]
KLK6	TTLPF4X	Definitive	Biomarker	[46]
KLRC1	TTC4IMS	Definitive	Biomarker	[47]
MAP2K5	TTV3O87	Definitive	Altered Expression	[48]
PLOD2	TT8MEUD	Definitive	Biomarker	[49]
PRKCZ	TTBSN0L	Definitive	Biomarker	[50]
S1PR2	TTVSMOH	Definitive	Altered Expression	[51]
------------------------------------------------------------------------------------


⏷ Show the Full List of 51 DTT(s)

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC11	DTWN7FC	Disputed	Genetic Variation	[52]
ATP2B1	DTJWQ1L	Strong	Altered Expression	[53]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
NDUFS3	DE741FI	Limited	Biomarker	[54]
AKR1A1	DED2FW3	moderate	Altered Expression	[55]
HSD17B7	DEDMWFX	Strong	Genetic Variation	[56]
------------------------------------------------------------------------------------

This Disease Is Related to 106 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ANKRD30A	OTJXYAE5	Limited	Biomarker	[57]
ARID3B	OTUP9MS4	Limited	Altered Expression	[58]
BRCA1	OT5BN6VH	Limited	Genetic Variation	[2]
BRMS1	OTV5A6LL	Limited	Altered Expression	[59]
CBX2	OTOQ5WS4	Limited	Biomarker	[60]
CLDN3	OT71MN9S	Limited	Altered Expression	[61]
FZD1	OTZATHVS	Limited	Altered Expression	[62]
GREB1	OTU6ZA26	Limited	Altered Expression	[61]
HAS2	OTTD3PAL	Limited	Altered Expression	[63]
HBP1	OTDPGGDV	Limited	Altered Expression	[64]
HRG	OTPLUFOG	Limited	Biomarker	[65]
ILRUN	OTE8FHQD	Limited	Biomarker	[66]
INTS2	OT2N5TCK	Limited	Genetic Variation	[11]
KANK1	OT2E7A6W	Limited	Altered Expression	[67]
LDHB	OT9B1CT3	Limited	Altered Expression	[61]
MYCBPAP	OT3W21WR	Limited	Biomarker	[68]
NCOR1	OT04XNOU	Limited	Altered Expression	[69]
PLCB2	OTPAHDGO	Limited	Altered Expression	[70]
RBM15B	OTRJ9DT7	Limited	Altered Expression	[71]
SMR3B	OTL5HNM8	Limited	Altered Expression	[72]
SNX27	OTVPS7S0	Limited	Altered Expression	[73]
ADGRE2	OTUYJVYG	Disputed	Biomarker	[74]
BLID	OT479VJV	Disputed	Genetic Variation	[75]
CEMIP	OTK80FYN	Disputed	Altered Expression	[76]
CHST11	OTNJJ5Q1	Disputed	Altered Expression	[77]
FABP7	OTRE2H4G	Disputed	Altered Expression	[78]
MB	OTYWYL2D	Disputed	Altered Expression	[79]
MTUS1	OTBPALMU	Disputed	Altered Expression	[80]
NOP14	OTKPM0Z5	Disputed	Altered Expression	[81]
PTPN12	OT5WA666	Disputed	Biomarker	[82]
QSOX1	OT4ZPK4P	Disputed	Biomarker	[83]
RBM3	OTAJ7R31	Disputed	Biomarker	[84]
SIM2	OT0QWHK4	Disputed	Biomarker	[85]
TOMM34	OTH6MITE	Disputed	Altered Expression	[86]
ARF6	OTVV7KJO	moderate	Biomarker	[68]
BAG1	OTRQNIA4	moderate	Altered Expression	[87]
CAP1	OTYM8A2N	moderate	Biomarker	[25]
CST6	OTZVHJTF	moderate	Biomarker	[88]
CTCF	OT8ZB70U	moderate	Altered Expression	[89]
DACH1	OTMKNAGG	moderate	Altered Expression	[45]
HACD1	OTEC7EP7	moderate	Biomarker	[25]
MAP1LC3B	OTUYHB84	moderate	Biomarker	[90]
MEST	OT8Q4U8Y	moderate	Altered Expression	[91]
NCSTN	OT5QBTA4	moderate	Biomarker	[92]
PELP1	OTVXQNOT	moderate	Biomarker	[93]
PI3	OT47MTC3	moderate	Altered Expression	[94]
PIP	OTH719AH	moderate	Biomarker	[95]
PXN	OTVMMUOF	moderate	Posttranslational Modification	[96]
SERPINB6	OT7G55IK	moderate	Biomarker	[25]
SH3BP4	OTVIRKW7	moderate	Altered Expression	[97]
SORBS1	OTWH8762	moderate	Biomarker	[25]
AFAP1L2	OTJBI0VN	Strong	Biomarker	[98]
ARHGAP18	OTYMJP6H	Strong	Biomarker	[99]
ARHGEF11	OTDOMEH6	Strong	Altered Expression	[100]
ATP2B2	OT1NPZ9T	Strong	Altered Expression	[53]
ATP2B4	OTMWFDAC	Strong	Altered Expression	[53]
CCL1	OT23NON8	Strong	Altered Expression	[101]
CHI3L2	OT26R3HQ	Strong	Altered Expression	[102]
CSTA	OT1K68KE	Strong	Biomarker	[103]
DGCR8	OT62LXE4	Strong	Altered Expression	[104]
DLGAP5	OTWCN39U	Strong	Biomarker	[105]
ELP3	OTT5UKSZ	Strong	Biomarker	[106]
GNL3	OTILGYO4	Strong	Altered Expression	[107]
GPAA1	OTWVRR35	Strong	Altered Expression	[108]
ITFG1	OTX0PCR3	Strong	Biomarker	[109]
NUSAP1	OT85HIJ5	Strong	Biomarker	[105]
PARD3	OTH5BPLO	Strong	Biomarker	[33]
PRPF38B	OTQLH551	Strong	Altered Expression	[110]
RAPH1	OTMQXW7S	Strong	Altered Expression	[111]
RNF126	OTTECSYY	Strong	Biomarker	[112]
RUVBL1	OTWV19L7	Strong	Biomarker	[109]
SEPTIN2	OT3G33TM	Strong	Biomarker	[40]
SEPTIN7	OTJI08YX	Strong	Biomarker	[40]
SMARCAD1	OT90AZTX	Strong	Biomarker	[113]
SPAM1	OTMPOB4E	Strong	Altered Expression	[114]
TBX3	OTM64N7K	Strong	Biomarker	[115]
THBS2	OTXET551	Strong	Biomarker	[116]
THRSP	OTKYE01L	Strong	Altered Expression	[117]
TRIM62	OT15YO6N	Strong	Genetic Variation	[118]
ARFGEF1	OTPAU0L4	Definitive	Biomarker	[119]
BCS1L	OT5PY5CY	Definitive	Biomarker	[120]
BHLHE22	OTZUQY5L	Definitive	Altered Expression	[121]
CERS6	OTOP4GV1	Definitive	Biomarker	[51]
CNTN3	OTC1274J	Definitive	Biomarker	[119]
ECT2	OTQDUCT6	Definitive	Biomarker	[122]
EPS8	OTZ6ES6V	Definitive	Altered Expression	[123]
FERMT2	OTZNPWWX	Definitive	Biomarker	[124]
FEV	OTYEC4IR	Definitive	Biomarker	[125]
G0S2	OT8FL49L	Definitive	Biomarker	[126]
GRB7	OTF8Y9XY	Definitive	Altered Expression	[127]
HERC3	OTWMKYD9	Definitive	Altered Expression	[128]
KRT14	OTUVZ1DW	Definitive	Biomarker	[129]
MAP2K4	OTZPZX11	Definitive	Genetic Variation	[130]
MARCHF3	OT89V4N5	Definitive	Biomarker	[131]
NRF1	OTOXWNV8	Definitive	Biomarker	[132]
PALB2	OT6DNDBG	Definitive	Genetic Variation	[133]
PRIMPOL	OTVK6K9J	Definitive	Altered Expression	[134]
PRKD3	OT987HJI	Definitive	Biomarker	[135]
PUM1	OTTMWP8L	Definitive	Biomarker	[136]
RAP1GAP	OTC31ONQ	Definitive	Altered Expression	[137]
S100A7	OTJFVJRF	Definitive	Altered Expression	[138]
SETD1A	OTVVWRIC	Definitive	Altered Expression	[139]
SIPA1	OTXY5RXC	Definitive	Biomarker	[140]
SLN	OTERIU75	Definitive	Biomarker	[141]
TM4SF1	OTY0ECQN	Definitive	Altered Expression	[142]
TRIM29	OT2DNESG	Definitive	Biomarker	[143]
------------------------------------------------------------------------------------


⏷ Show the Full List of 106 DOT(s)

References

1	Bcl6/p53 expression, macrophages/mast cells infiltration and microvascular density in invasive breast carcinoma.Oncotarget. 2018 Apr 27;9(32):22727-22740. doi: 10.18632/oncotarget.25220. eCollection 2018 Apr 27.
2	Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.Breast Cancer Res Treat. 2019 Jun;175(3):749-754. doi: 10.1007/s10549-019-05199-8. Epub 2019 Mar 20.
3	In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas.J Exp Med. 1999 Nov 15;190(10):1417-26. doi: 10.1084/jem.190.10.1417.
4	Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.Breast Cancer Res Treat. 2011 Jan;125(1):279-87. doi: 10.1007/s10549-010-1139-x. Epub 2010 Sep 1.
5	Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines.BMC Cancer. 2012 Oct 30;12:501. doi: 10.1186/1471-2407-12-501.
6	Tyrosine kinase-deficient EphB6 receptor-dependent alterations in proteomic profiles of invasive breast carcinoma cells as determined by difference gel electrophoresis.Cancer Genomics Proteomics. 2010 Sep-Oct;7(5):253-60.
7	Proteomic phenotyping: metastatic and invasive breast cancer.Cancer Lett. 2004 Jul 16;210(2):245-53. doi: 10.1016/j.canlet.2004.01.019.
8	High levels of -glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.
9	Interleukin-13 receptor alpha 2 expression in tumor cells is associated with reduced disease-free survival in patients with luminal subtype invasive breast cancer.Tumour Biol. 2018 Jun;40(6):1010428318783657. doi: 10.1177/1010428318783657.
10	Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.Clin Breast Cancer. 2018 Aug;18(4):e643-e650. doi: 10.1016/j.clbc.2017.11.008. Epub 2017 Nov 21.
11	Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer.Cancer Res. 1995 Feb 1;55(3):467-71.
12	PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.J Clin Invest. 2007 Dec;117(12):4009-21. doi: 10.1172/JCI32424.
13	ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.Oncotarget. 2014 Jan 30;5(2):351-62. doi: 10.18632/oncotarget.1449.
14	Prediction of recurrence risk in early breast cancer using human epidermal growth factor 2 and cyclin A2.Chin Med J (Engl). 2010 Feb 20;123(4):431-7.
15	Integrin 21 mediates tyrosine phosphorylation of vascular endothelial cadherin induced by invasive breast cancer cells.J Biol Chem. 2012 Sep 21;287(39):32981-92. doi: 10.1074/jbc.M112.395905. Epub 2012 Jul 25.
16	KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization.J Biol Chem. 2009 Jun 19;284(25):16791-16798. doi: 10.1074/jbc.M808919200. Epub 2009 May 1.
17	Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).BMC Cancer. 2009 Jul 29;9:257. doi: 10.1186/1471-2407-9-257.
18	MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.Oncogene. 2010 Aug 5;29(31):4399-411. doi: 10.1038/onc.2010.198. Epub 2010 May 31.
19	Identifying the molecular signature of the interstitial deletion 7q subgroup of uterine leiomyomata using a paired analysis.Genes Chromosomes Cancer. 2009 Oct;48(10):865-85. doi: 10.1002/gcc.20692.
20	Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model.Oncogene. 2013 Dec 5;32(49):5551-62. doi: 10.1038/onc.2013.207. Epub 2013 Jun 10.
21	HIF-1 overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.PLoS One. 2013;8(2):e56055. doi: 10.1371/journal.pone.0056055. Epub 2013 Feb 8.
22	FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.Cancer Chemother Pharmacol. 2019 Oct;84(4):861-872. doi: 10.1007/s00280-019-03923-1. Epub 2019 Aug 19.
23	Follistatin Expression in Human Invasive Breast Tumors: Pathologic and Clinical Associations.Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):108-112. doi: 10.1097/PAI.0000000000000385.
24	Total tumor load assessed by one-step nucleic acid amplification assay as an intraoperative predictor for non-sentinel lymph node metastasis in breast cancer.Breast. 2017 Apr;32:33-36. doi: 10.1016/j.breast.2016.12.011. Epub 2016 Dec 25.
25	Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.Breast Cancer Res Treat. 2016 Aug;159(1):31-9. doi: 10.1007/s10549-016-3917-6. Epub 2016 Jul 25.
26	Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.Clin Breast Cancer. 2019 Dec;19(6):e741-e747. doi: 10.1016/j.clbc.2019.05.014. Epub 2019 Jun 6.
27	Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells.Oncogene. 2019 Apr;38(15):2860-2875. doi: 10.1038/s41388-018-0618-0. Epub 2018 Dec 14.
28	Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.Br J Cancer. 2019 Oct;121(9):776-785. doi: 10.1038/s41416-019-0589-0. Epub 2019 Sep 27.
29	Identification, localization and characterization of the human gamma-synuclein gene.Hum Genet. 1998 Jul;103(1):106-12. doi: 10.1007/s004390050792.
30	Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion.Front Oncol. 2019 Oct 23;9:1074. doi: 10.3389/fonc.2019.01074. eCollection 2019.
31	The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma insitu.Histopathology. 2019 Jun;74(7):1025-1035. doi: 10.1111/his.13835. Epub 2019 Apr 14.
32	Verifiable fully outsourced attribute-based signcryption system for IoT eHealth big data in cloud computing.Math Biosci Eng. 2019 Apr 22;16(5):3561-3594. doi: 10.3934/mbe.2019178.
33	Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis.Cancer Cell. 2012 Nov 13;22(5):601-14. doi: 10.1016/j.ccr.2012.10.003.
34	Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery.J Exp Clin Cancer Res. 2015 Feb 5;34(1):12. doi: 10.1186/s13046-015-0128-7.
35	Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression.J Pathol. 2004 Oct;204(2):121-30. doi: 10.1002/path.1625.
36	Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.Ann Surg Oncol. 2017 Nov;24(12):3780-3787. doi: 10.1245/s10434-017-5907-2. Epub 2017 Jun 20.
37	OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.Proteomics. 2019 Nov;19(21-22):e1800446. doi: 10.1002/pmic.201800446. Epub 2019 Aug 8.
38	The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.Sci Signal. 2015 Feb 17;8(364):ra18. doi: 10.1126/scisignal.2005547.
39	High nuclear MSK1 is associated with longer survival in breast cancer patients.J Cancer Res Clin Oncol. 2018 Mar;144(3):509-517. doi: 10.1007/s00432-018-2579-7. Epub 2018 Jan 11.
40	The requirement of SEPT2 and SEPT7 for migration and invasion in human breast cancer via MEK/ERK activation.Oncotarget. 2016 Sep 20;7(38):61587-61600. doi: 10.18632/oncotarget.11402.
41	Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.Tumour Biol. 2015 Sep;36(9):6833-8. doi: 10.1007/s13277-015-3390-6. Epub 2015 Apr 7.
42	RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.Pathol Res Pract. 2009;205(6):403-8. doi: 10.1016/j.prp.2008.12.014. Epub 2009 Feb 20.
43	BST-2 promotes survival in circulation and pulmonary metastatic seeding of breast cancer cells.Sci Rep. 2018 Dec 4;8(1):17608. doi: 10.1038/s41598-018-35710-y.
44	Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.Breast Cancer. 2011 Apr;18(2):120-3. doi: 10.1007/s12282-009-0175-z. Epub 2009 Oct 8.
45	Forkhead Box Q1 Is a Novel Target of Breast Cancer Stem Cell Inhibition by Diallyl Trisulfide.J Biol Chem. 2016 Jun 24;291(26):13495-508. doi: 10.1074/jbc.M116.715219. Epub 2016 Apr 29.
46	An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.J Proteomics. 2016 Jun 16;142:114-21. doi: 10.1016/j.jprot.2016.04.050. Epub 2016 May 7.
47	CD16(+)NKG2A(high) Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes.Cancer Immunol Res. 2019 Feb;7(2):208-218. doi: 10.1158/2326-6066.CIR-18-0085. Epub 2018 Dec 4.
48	Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.Oncol Rep. 2017 Jan;37(1):83-90. doi: 10.3892/or.2016.5256. Epub 2016 Nov 18.
49	Tumor-secreted PAI-1 promotes breast cancer metastasis via the induction of adipocyte-derived collagen remodeling.Cell Commun Signal. 2019 Jun 6;17(1):58. doi: 10.1186/s12964-019-0373-z.
50	PKC Promotes Breast Cancer Invasion by Regulating Expression of E-cadherin and Zonula Occludens-1 (ZO-1) via NFB-p65.Sci Rep. 2015 Jul 28;5:12520. doi: 10.1038/srep12520.
51	C16ceramide and sphingosine1phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation.Oncol Rep. 2018 Nov;40(5):2977-2987. doi: 10.3892/or.2018.6689. Epub 2018 Sep 7.
52	Association between breast cancer risk and the wild-type allele of human ABC transporter ABCC11.Anticancer Res. 2010 Dec;30(12):5189-94.
53	Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.BMC Cancer. 2018 Oct 23;18(1):1029. doi: 10.1186/s12885-018-4945-x.
54	Biomarker signatures of mitochondrial NDUFS3 in invasive breast carcinoma.Biochem Biophys Res Commun. 2011 Sep 9;412(4):590-5. doi: 10.1016/j.bbrc.2011.08.003. Epub 2011 Aug 16.
55	Class I alcohol dehydrogenase is highly expressed in normal human mammary epithelium but not in invasive breast cancer: implications for breast carcinogenesis.Cancer Res. 2003 Jun 15;63(12):3092-100.
56	High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.Clin Cancer Res. 2003 Jun;9(6):2288-93.
57	Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases.Clin Cancer Res. 2006 May 1;12(9):2745-51. doi: 10.1158/1078-0432.CCR-05-2192.
58	ARID3B expression in primary breast cancers and breast cancer-derived cell lines.Cell Oncol (Dordr). 2014 Aug;37(4):289-96. doi: 10.1007/s13402-014-0185-5. Epub 2014 Aug 14.
59	Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.Clin Cancer Res. 2006 Nov 1;12(21):6410-4. doi: 10.1158/1078-0432.CCR-06-1347.
60	A novel approach to modelling transcriptional heterogeneity identifies the oncogene candidate CBX2 in invasive breast carcinoma.Br J Cancer. 2019 Apr;120(7):746-753. doi: 10.1038/s41416-019-0387-8. Epub 2019 Mar 1.
61	Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics.Oncogene. 2006 Apr 13;25(16):2328-38. doi: 10.1038/sj.onc.1209265.
62	Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma.Int J Oncol. 2004 Nov;25(5):1337-42.
63	Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer.Cancer Res. 2005 Jul 15;65(14):6139-50. doi: 10.1158/0008-5472.CAN-04-1622.
64	Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer.Cancer Res. 2007 Jul 1;67(13):6136-45. doi: 10.1158/0008-5472.CAN-07-0567.
65	Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.Breast Cancer Res Treat. 2003 Aug;80(3):353-61. doi: 10.1023/A:1024929522376.
66	A novel biomarker C6orf106 promotes the malignant progression of breast cancer.Tumour Biol. 2015 Sep;36(10):7881-9. doi: 10.1007/s13277-015-3500-5. Epub 2015 May 8.
67	Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.Breast Cancer Res Treat. 2020 Jan;179(2):349-357. doi: 10.1007/s10549-019-05466-8. Epub 2019 Nov 2.
68	Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis.Proc Natl Acad Sci U S A. 2006 May 2;103(18):7036-41. doi: 10.1073/pnas.0509166103. Epub 2006 Apr 24.
69	NCOR1 mRNA is an independent prognostic factor for breast cancer.Cancer Lett. 2006 Jun 8;237(1):123-9. doi: 10.1016/j.canlet.2005.05.046. Epub 2005 Jul 12.
70	Ectopic expression of PLC-2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.Mol Carcinog. 2019 May;58(5):708-721. doi: 10.1002/mc.22964. Epub 2019 Jan 16.
71	BAP1 expression is prognostic in breast and uveal melanoma but not colon cancer and is highly positively correlated with RBM15B and USP19.PLoS One. 2019 Feb 4;14(2):e0211507. doi: 10.1371/journal.pone.0211507. eCollection 2019.
72	Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.Br J Cancer. 2006 Aug 7;95(3):347-54. doi: 10.1038/sj.bjc.6603261. Epub 2006 Jul 11.
73	SNX27-retromer assembly recycles MT1-MMP to invadopodia and promotes breast cancer metastasis.J Cell Biol. 2020 Jan 6;219(1):e201812098. doi: 10.1083/jcb.201812098.
74	Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival.Oncol Rep. 2011 Mar;25(3):619-27. doi: 10.3892/or.2010.1117. Epub 2010 Dec 21.
75	Frequent loss of the BLID gene in early-onset breast cancer.Cytogenet Genome Res. 2011;135(1):19-24. doi: 10.1159/000330265. Epub 2011 Aug 12.
76	Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration.J Natl Cancer Inst. 2013 Sep 18;105(18):1402-16. doi: 10.1093/jnci/djt224. Epub 2013 Aug 29.
77	Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells.Breast Cancer Res. 2011 Jun 9;13(3):R58. doi: 10.1186/bcr2895.
78	The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer.Breast Cancer Res Treat. 2010 May;121(1):41-51. doi: 10.1007/s10549-009-0450-x. Epub 2009 Jul 10.
79	Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype.Br J Cancer. 2010 Jun 8;102(12):1736-45. doi: 10.1038/sj.bjc.6605702.
80	8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis.PLoS One. 2009 Oct 1;4(10):e7239. doi: 10.1371/journal.pone.0007239.
81	NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/-catenin pathway.Oncotarget. 2015 Sep 22;6(28):25701-14. doi: 10.18632/oncotarget.4573.
82	Clinicopathological significance of PTPN12 expression in human breast cancer.Braz J Med Biol Res. 2012 Dec;45(12):1334-40. doi: 10.1590/s0100-879x2012007500163. Epub 2012 Oct 9.
83	Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer.Breast Cancer Res. 2013 Mar 28;15(2):R28. doi: 10.1186/bcr3407.
84	High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer.J Breast Cancer. 2018 Sep;21(3):288-296. doi: 10.4048/jbc.2018.21.e34. Epub 2018 Aug 28.
85	Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s).Oncogene. 2013 May 23;32(21):2631-9. doi: 10.1038/onc.2012.286. Epub 2012 Jul 9.
86	TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome.Breast Cancer Res Treat. 2012 Nov;136(2):419-27. doi: 10.1007/s10549-012-2249-4. Epub 2012 Oct 4.
87	BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma.Breast Cancer Res Treat. 2004 Apr;84(3):203-13. doi: 10.1023/B:BREA.0000019951.32001.93.
88	Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.Breast Cancer Res. 2010;12(6):R100. doi: 10.1186/bcr2783. Epub 2010 Nov 23.
89	Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1.Br J Cancer. 2004 Oct 18;91(8):1591-6. doi: 10.1038/sj.bjc.6602144.
90	Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer.Histopathology. 2013 Jan;62(2):275-86. doi: 10.1111/his.12002. Epub 2012 Nov 8.
91	Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer.Hum Mol Genet. 2002 Jun 1;11(12):1449-53. doi: 10.1093/hmg/11.12.1449.
92	The role of genes co-amplified with nicastrin in breast invasive carcinoma.Breast Cancer Res Treat. 2014 Jan;143(2):393-401. doi: 10.1007/s10549-013-2805-6. Epub 2013 Dec 13.
93	Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of B Kinase and Inflammatory Cross-talk with Macrophages.J Biol Chem. 2017 Jan 6;292(1):339-350. doi: 10.1074/jbc.M116.739847. Epub 2016 Nov 23.
94	Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.Breast Cancer Res. 2014;16(6):3417. doi: 10.1186/s13058-014-0497-4.
95	Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.J Clin Pathol. 2017 Nov;70(11):926-934. doi: 10.1136/jclinpath-2016-204137. Epub 2017 Apr 20.
96	Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.Breast Cancer Res Treat. 2012 Aug;134(3):989-1004. doi: 10.1007/s10549-012-1986-8. Epub 2012 Mar 21.
97	miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer.J Pathol. 2013 May;230(1):28-38. doi: 10.1002/path.4178. Epub 2013 Mar 21.
98	Expression of XB130 in human ductal breast cancer.Int J Clin Exp Pathol. 2015 May 1;8(5):5300-8. eCollection 2015.
99	Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.Br J Cancer. 2017 Oct 10;117(8):1176-1184. doi: 10.1038/bjc.2017.261. Epub 2017 Aug 22.
100	The exon 38-containing ARHGEF11 splice isoform is differentially expressed and is required for migration and growth in invasive breast cancer cells.Oncotarget. 2017 Sep 18;8(54):92157-92170. doi: 10.18632/oncotarget.20985. eCollection 2017 Nov 3.
101	CCL1 is a major regulatory T cell attracting factor in human breast cancer.BMC Cancer. 2018 Dec 20;18(1):1278. doi: 10.1186/s12885-018-5117-8.
102	Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy.Oncoimmunology. 2018 Mar 13;7(6):e1436922. doi: 10.1080/2162402X.2018.1436922. eCollection 2018.
103	Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.J Pathol. 2017 Dec;243(4):496-509. doi: 10.1002/path.4990. Epub 2017 Oct 31.
104	Complexity in regulation of microRNA machinery components in invasive breast carcinoma.Pathol Oncol Res. 2014 Jul;20(3):697-705. doi: 10.1007/s12253-014-9750-5. Epub 2014 Feb 27.
105	Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression.Med Sci Monit. 2018 Nov 26;24:8553-8564. doi: 10.12659/MSM.910364.
106	Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer.J Exp Med. 2016 Oct 17;213(11):2503-2523. doi: 10.1084/jem.20160397. Epub 2016 Oct 10.
107	Nucleostemin expression in breast cancer is a marker of more aggressive phenotype and unfavorable patients' outcome: A STROBE-compliant article.Medicine (Baltimore). 2019 Mar;98(9):e14744. doi: 10.1097/MD.0000000000014744.
108	Overexpression of glycosylphosphatidylinositol (GPI) transamidase subunits phosphatidylinositol glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer.Cancer Res. 2006 Oct 15;66(20):9829-36. doi: 10.1158/0008-5472.CAN-06-0506.
109	RUVBL1-ITFG1 interaction is required for collective invasion in breast cancer.Biochim Biophys Acta Gen Subj. 2017 Jul;1861(7):1788-1800. doi: 10.1016/j.bbagen.2017.03.016. Epub 2017 Mar 21.
110	The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.Oncotarget. 2017 Nov 18;8(68):112245-112257. doi: 10.18632/oncotarget.22496. eCollection 2017 Dec 22.
111	Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.Breast Cancer Res Treat. 2018 Nov;172(1):61-68. doi: 10.1007/s10549-018-4891-y. Epub 2018 Jul 28.
112	RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.Clin Cancer Res. 2018 Apr 1;24(7):1629-1643. doi: 10.1158/1078-0432.CCR-17-2242. Epub 2018 Jan 11.
113	SMARCAD1 knockdown uncovers its role in breast cancer cell migration, invasion, and metastasis.Expert Opin Ther Targets. 2016 Sep;20(9):1035-43. doi: 10.1080/14728222.2016.1195059. Epub 2016 Jun 13.
114	Expression of PH-20 in normal and neoplastic breast tissue.J Surg Res. 2002 Apr;103(2):203-7. doi: 10.1006/jsre.2002.6351.
115	TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG.J Pathol. 2019 Jun;248(2):191-203. doi: 10.1002/path.5245. Epub 2019 Apr 8.
116	Targeted matrisome analysis identifies thrombospondin-2 and tenascin-C in aligned collagen stroma from invasive breast carcinoma.Sci Rep. 2018 Aug 28;8(1):12941. doi: 10.1038/s41598-018-31126-w.
117	Spot 14: A marker of aggressive breast cancer and a potential therapeutic target.Endocrinology. 2006 Sep;147(9):4048-55. doi: 10.1210/en.2006-0463. Epub 2006 Jun 29.
118	DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.PLoS Med. 2009 May 26;6(5):e1000068. doi: 10.1371/journal.pmed.1000068. Epub 2009 May 5.
119	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.J Clin Oncol. 2017 Apr 10;35(11):1179-1188. doi: 10.1200/JCO.2016.70.3116. Epub 2017 Feb 13.
120	Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database.Breast Cancer Res Treat. 2018 Nov;172(1):201-208. doi: 10.1007/s10549-018-4881-0. Epub 2018 Aug 6.
121	Novel mutations involving I-, IIA-, or IVB-tubulin isotypes with functional resemblance to III-tubulin in breast cancer.Protoplasma. 2017 May;254(3):1163-1173. doi: 10.1007/s00709-016-1060-1. Epub 2016 Dec 9.
122	Expression and prognostic significance of ECT2 in invasive breast cancer.J Clin Pathol. 2018 May;71(5):442-445. doi: 10.1136/jclinpath-2017-204569. Epub 2017 Oct 19.
123	Eps8 regulates cellular proliferation and migration of breast cancer.Int J Oncol. 2015 Jan;46(1):205-14. doi: 10.3892/ijo.2014.2710. Epub 2014 Oct 17.
124	Kindlin-2 could influence breast nodule elasticity and improve lymph node metastasis in invasive breast cancer.Sci Rep. 2017 Jul 28;7(1):6753. doi: 10.1038/s41598-017-07075-1.
125	Dual-Time-Point FDG Uptake Correlates with Prognostic Factors of Invasive Breast Cancer: Clinical Usefulness of Early Delayed Scanning.Diagnostics (Basel). 2019 Apr 9;9(2):40. doi: 10.3390/diagnostics9020040.
126	G0/G1 Switch 2 Induces Cell Survival and Metastasis through Integrin-Mediated Signal Transduction in Human Invasive Breast Cancer Cells.Biomol Ther (Seoul). 2019 Nov 1;27(6):591-602. doi: 10.4062/biomolther.2019.063.
127	GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma.Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):553-558. doi: 10.1097/PAI.0000000000000349.
128	Np63 down-regulates c-Myc modulator MM1 via E3 ligase HERC3 in the regulation of cell senescence.Cell Death Differ. 2018 Dec;25(12):2118-2129. doi: 10.1038/s41418-018-0132-5. Epub 2018 Jun 7.
129	Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution.Sci Rep. 2017 Nov 28;7(1):16459. doi: 10.1038/s41598-017-16492-1.
130	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.Mod Pathol. 2017 Apr;30(4):509-518. doi: 10.1038/modpathol.2016.229. Epub 2017 Jan 13.
131	Breast Cancer Recurrence in the Nipple-Areola Complex After Nipple-Sparing Mastectomy With Immediate Breast Reconstruction for Invasive Breast Cancer.JAMA Surg. 2019 Nov 1;154(11):1030-1037. doi: 10.1001/jamasurg.2019.2959.
132	Nuclear Respiratory Factor 1 Acting as an Oncoprotein Drives Estrogen-Induced Breast Carcinogenesis.Cells. 2018 Nov 27;7(12):234. doi: 10.3390/cells7120234.
133	Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?.BMC Cancer. 2018 Feb 8;18(1):165. doi: 10.1186/s12885-018-4028-z.
134	PrimPol prevents APOBEC/AID family mediated DNA mutagenesis.Nucleic Acids Res. 2016 Jun 2;44(10):4734-44. doi: 10.1093/nar/gkw123. Epub 2016 Feb 28.
135	Oncogenic Protein Kinase D3 Regulating Networks in Invasive Breast Cancer.Int J Biol Sci. 2017 May 16;13(6):748-758. doi: 10.7150/ijbs.18472. eCollection 2017.
136	Selecting housekeeping genes as references for the normalization of quantitative PCR data in breast cancer.Clin Transl Oncol. 2014 Feb;16(2):184-90. doi: 10.1007/s12094-013-1058-5. Epub 2013 May 30.
137	Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation.Neoplasia. 2018 Sep;20(9):951-963. doi: 10.1016/j.neo.2018.07.002. Epub 2018 Aug 22.
138	Molecular and cellular impact of Psoriasin (S100A7) on the healing of human wounds.Exp Ther Med. 2017 May;13(5):2151-2160. doi: 10.3892/etm.2017.4275. Epub 2017 Mar 28.
139	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.PLoS One. 2019 Apr 16;14(4):e0209134. doi: 10.1371/journal.pone.0209134. eCollection 2019.
140	Nuclear SIPA1 activates integrin 1 promoter and promotes invasion of breast cancer cells.Oncogene. 2015 Mar 12;34(11):1451-62. doi: 10.1038/onc.2014.36. Epub 2014 Apr 7.
141	Dynamic contrast-enhanced and diffusion-weighted MRI of invasive breast cancer for the prediction of sentinel lymph node status.J Magn Reson Imaging. 2020 Feb;51(2):615-626. doi: 10.1002/jmri.26865. Epub 2019 Jul 16.
142	Upregulation of transmembrane 4 L6 family member 1 predicts poor prognosis in invasive breast cancer: A STROBE-compliant article.Medicine (Baltimore). 2017 Dec;96(52):e9476. doi: 10.1097/MD.0000000000009476.
143	TRIM29 suppresses TWIST1 and invasive breast cancer behavior.Cancer Res. 2014 Sep 1;74(17):4875-87. doi: 10.1158/0008-5472.CAN-13-3579. Epub 2014 Jun 20.